Novel Targets @TargetsPodcast was a science podcast that ran from 2015 to 2018.

Over 4 seasons it brought to life the science and people involved in the development of innovative new drugs, gene and cell therapies. It captured a landmark period in cancer drug development and cancer immunotherapy research.

It sought to inform, educate and create awareness; it occasionally entertained.

The show looked at emerging new targets and approaches that could make a difference to the lives of patients. It discussed data from clinical trials and engaged experts.

It reached a broad global audience of “influencers” and stakeholders in the cancer research community.

Sally Church, PhD

Sally was the executive producer of Novel Targets and ensured the scientific accuracy of the show’s output.

A digital media entrepreneur, she’s a member of the National Association of Science Writers (NASW) and Association of Health Care Journalists (AHCJ).

Over the last 10+ years she’s written close to two thousand posts on the science driving cancer drug development, firstly on Pharma Strategy Blog and then on her independent, subscription funded publication Biotech Strategy Blog.

Follow Sally on Twitter: @MaverickNY


Genentech Corporate LogoGenentech (@Genentech) sponsored Novel Targets for 4 seasons ending with Episode 26, “Coming Full Circle.”

Each episode Genentech supported usually featured a short vignette or mini-interview with one of their scientists that highlighted their passion in “helping people combat the world’s hardest-to-treat diseases.

The Loncar Cancer Immunotherapy Index sponsored Episode 14: Cell Therapy Pioneers.

It reached No 21 in the US iTunes/Apple Podcasts chart for Medicine related podcasts.

We’re grateful for all the sponsor support we’ve obtained without which the podcast would not have happened!

Editorial Policy

If we did mention any products or people from any sponsor (outside of the sponsorship mention) in any episode, then it’s because we thought they merited commentary or inclusion.

The podcast was editorially independent – sponsors had no control over content, who we interviewed, what topics we talked about or the questions we asked!